2 recruiting, 1 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Georgiamune Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407 GIM-407, Placebo - Healthy Volunteers | Phase 1 | Completed | Georgiamune Inc | 48 | 2024-09-02 | 2025-07-10 |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors GIM-531, Anti-PD-1 monoclonal antibody - Melanoma Stage IV, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 117 | 2024-05-09 | 2026-08-14 |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies GIM122 - Advanced Solid Malignancies | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 111 | 2023-12-12 | 2026-08-17 |
Melanoma (1)
spartalizumab (1)
United States (2) · Australia (1)
Omid Hamid, MD (1)